Phase 1 trial of gemtuzumab ozogamicin in combination with enocitabine and daunorubicin for elderly patients with relapsed or refractory acute myeloid leukemia: Japan Adult Leukemia Study Group (JALSG)-GML208 study (Q50913503)

From Wikidata

Jump to navigation Jump to search

scientific article published on 6 September 2012

Language	Label	Description	Also known as
English	Phase 1 trial of gemtuzumab ozogamicin in combination with enocitabine and daunorubicin for elderly patients with relapsed or refractory acute myeloid leukemia: Japan Adult Leukemia Study Group (JALSG)-GML208 study	scientific article published on 6 September 2012

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/22956429

Phase 1 trial of gemtuzumab ozogamicin in combination with enocitabine and daunorubicin for elderly patients with relapsed or refractory acute myeloid leukemia: Japan Adult Leukemia Study Group (JALSG)-GML208 study (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/22956429

phase I clinical trial

0 references

1 reference

based on heuristic

inferred from title

acute myeloid leukemia

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Kazuma Ohyashiki

6

object named as

Kazuma Ohyashiki

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

author name string

Yoshikazu Ito

1

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/22956429

Atsushi Wakita

2

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/22956429

Satoru Takada

3

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/22956429

Masahiro Mihara

4

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/22956429

Moritaka Gotoh

5

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/22956429

Shigeki Ohtake

7

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/22956429

Shuichi Miyawaki

8

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/22956429

Kazunori Ohnishi

9

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/22956429

Tomoki Naoe

10

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/22956429

publication date

6 September 2012

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/22956429

International Journal of Hematology

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/22956429

96

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/22956429

4

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/22956429

485-491

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/22956429

Therapeutic advances in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1165-Z

21 January 2018

Acute myeloid leukemia in the elderly

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1165-Z

21 January 2018

Treatment of older patients with AML.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1165-Z

21 January 2018

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1165-Z

21 January 2018

Current use and future development of gemtuzumab ozogamicin

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1165-Z

21 January 2018

Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin).

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1165-Z

21 January 2018

Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final results of Japanese multicenter cooperative study

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1165-Z

21 January 2018

Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1165-Z

21 January 2018

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1165-Z

21 January 2018

Randomized comparison of fixed-schedule versus response-oriented individualized induction therapy and use of ubenimex during and after consolidation therapy for elderly patients with acute myeloid leukemia: the JALSG GML200 Study.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1165-Z

21 January 2018

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1165-Z

21 January 2018

First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1165-Z

21 January 2018

High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1165-Z

21 January 2018

Gemtuzumab ozogamicin, cytosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1165-Z

21 January 2018

Gemtuzumab ozogamicin in combination with attenuated doses of standard induction chemotherapy can successfully induce complete remission without increasing toxicity in patients with acute myeloid leukemia aged 55 or older

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1165-Z

21 January 2018

Pilot Study of Gemtuzumab Ozogamicin (GO), Fludarabine, Cytarabine and Idarubicin Combined Regimen (GO-FLAI) as First-Line Induction Therapy plus GO Alone as Consolidation Therapy for Elderly Acute Myeloid Leukemia Patients

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1165-Z

21 January 2018

Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/22956429

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22956429

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/22956429

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and compa

1 reference

https://pubmed.ncbi.nlm.nih.gov/22956429

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties

1 reference

https://pubmed.ncbi.nlm.nih.gov/22956429

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro

1 reference

https://pubmed.ncbi.nlm.nih.gov/22956429

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I trial of gemtuzumab ozogamicin in intensive combination chemotherapy for relapsed or refractory adult acute myeloid leukemia (AML): Japan Adult Leukemia Study Group (JALSG)-AML206 study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22956429

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of acute myeloid leukemia patients aged more than 75 years: results of the E-AML-01 trial of the Japanese Elderly Leukemia and Lymphoma Study Group (JELLSG)

1 reference

https://pubmed.ncbi.nlm.nih.gov/22956429

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S12185-012-1165-Z

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/22956429

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/22956429

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50913503&oldid=2263212322"